News
Figure 1: Amount of public funding for Alzheimer disease research in Japan for the past 10 years by type of funding (basic, blue; competitive, purple; special budget for genome research, ivory).
Scientists in Japan may be at the start of a truly monumental accomplishment: a vaccine that can slow or delay the progression of Alzheimer’s disease. In preliminary research released this week ...
Research from Kanazawa University on 8,766 older adults using MRI scans revealed a 3 percent reduction in brain white matter ...
The world’s biggest health challenge this century is not cancer, heart disease or stroke; but dementia, according to Lenny Shallcross, executive director of the World Dementia Council, which ...
A stroke drug called GAI-17 protected mouse brains even six hours after damage began—and may one day help fight Alzheimer’s ...
The optimism about Alzheimer’s was palpable in Kyoto, along with the cherry blossoms and beginning of Golden Week. The WHO’s target date of 2025 for finding a cure now seems to be in reach ...
FUKUOKA—Testosterone, a sex hormone produced primarily in male testes, could be the reason why men are less likely than women to develop Alzheimer’s disease, researchers with Kyushu University here ...
Japanese researchers have confirmed a way to predict the onset of Alzheimer’s disease with a high degree of probability, by checking blood for the presence of a certain type of abnormal protein ...
The Alzheimer's Association estimates that more than 4.6 million people are living with dementia in Japan and it is expected to rise significantly as the ... Research Reports. Personal Finance.
Eli Lilly LLY announced that its Alzheimer's disease (AD) drug Kisunla (donanemab) has been approved for use in Japan. The drug will treat early symptomatic AD in adults with mild cognitive ...
According to Japan's National Institute of Population and Social Security Research, people aged over 65 are expected to account for 32.3% of the country's population by 2035.
Meanwhile, 2022 also saw Roche receive a breakthrough designation from the FDA for its in vitro Alzheimer’s test—an amyloid plasma panel that also measures blood levels of phosphorylated tau ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results